Monthly Prescribing Reference

Albuterol/Budesonide Rescue Inhaler Airsupra Now Available for Asthma Patients

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...
Monthly Prescribing Reference

Albuterol/Budesonide Fixed-Dose Combo Rescue Inhaler to Get FDA Review

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...
MedPage Today

Inhaled Steroid for Early COVID-19 Passes Another Test

Inhaled budesonide (Pulmicort), commonly used in asthma, helped COVID-19 outpatients at extra risk for severe illness recover more quickly relative to standard care in the pragmatic PRINCIPLE trial, ...
Healio

Fixed-dose albuterol-budesonide inhaler lowers severe exacerbation risk in mild asthma

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.
FiercePharma

AstraZeneca to discontinue production of PULMICORT® pMDI, other respiratory medicines not affected

AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...
FiercePharma

US District Court rules one PULMICORT RESPULES® (budesonide inhalation suspension) patent invalid and another patent not infringed

AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...